US FDA advisers to review Eli Lilly Alzheimer's drug
By Bhanvi Satija and Julie Steenhuysen
June 10 (Reuters) -An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's LLY.N experimental Alzheimer's drug donanemab.
Donanemab, if approved, would compete with Eisai 4523.T and Biogen's BIIB.O Leqembi. Both drugs are designed to remove toxic beta amyloid plaques from the brains of people with early Alzheimer's disease.
The antibody treatments, which succeeded in slowing disease progression in clinical trials, follow three decades of failed attempts to find drugs to fight the fatal, mind-wasting disease.
The experts are being asked to discuss whether analyses of trial data to be presented by the FDA and the company show whether the benefits of donanemab in slowing cognitive decline in patients with early stage disease outweigh its safety risks.
The FDA is not obligated to follow the recommendations of its outside advisers but typically does so.
The Lilly drug and others in its class can cause potentially fatal swelling or bleeding in the brain. Three people in the donanemab trial died from complications linked to the treatment.
"From the beginning, safety has been a concern with these new anti-amyloid monoclonal antibodies," said Dr. Joshua Cahan from Northwestern's Feinberg School of Medicine.
With its approval of Leqembi, the FDA issued its strongest "boxed" warning about the risk of potentially dangerous brain swelling and bleeding for the entire class of amyloid-lowering drugs. FDA drug reviewers said last week that if approved, donanemab's risks of brain swelling and bleeding would be described in the boxed warning.
At least four Wall Street analysts said last week that FDA staff reviewers did not raise any serious red flags and they expect donanemab to win approval.
Wall Street analysts on average expect donanemab sales of about $631 million next year, according to LSEG estimates.
More than 6 million Americans have some form of the memory-robbing condition, according to the Alzheimer's Association. That figure is projected to rise to nearly 13 million by 2050.
Reporting by Bhanvi Satija in Bengaluru and Julie Steenhuysen in Chicago; Editing by Caroline Humer and Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
